Table 6.
Development of symptoms between baseline and 2-year follow-up
| Group/Symptom | Baseline | 2-y Follow-Up | Relative Risk (95% CI) |
|---|---|---|---|
| Regular-dose | |||
| Pain attacks | 5 (25.0) | 7 (29.2) | 1.10 (0.62 to 1.96) |
| Permanent pain | 8 (40.0) | 9 (37.5) | 0.95 (0.54 to 1.67) |
| Gastrointestinal pain | 5 (25.0) | 8 (33.3) | 1.19 (0.69 to 2.06) |
| Diarrhea | 5 (25.0) | 8 (33.3) | 1.19 (0.69 to 2.06) |
| Dose-reduction-switch | |||
| Pain attacks | 6 (26.1) | 9 (33.3) | 1.17 (0.69 to 1.97) |
| Permanent pain | 13 (56.5) | 14 (51.9) | 0.92 (0.55 to 1.53) |
| Gastrointestinal pain | 3 (13.0) | 12 (44.4) | 1.87 (1.18 to 2.95) |
| Diarrhea | 7 (30.4) | 13 (48.1) | 1.44 (0.87 to 2.38) |
| Switch | |||
| Pain attacks | 1 (3.0) | 3 (9.7) | 1.61 (0.86 to 3.01) |
| Permanent pain | 6 (18.2) | 7 (21.9) | 1.12 (0.63 to 2.00) |
| Gastrointestinal pain | 3 (9.1) | 9 (28.1) | 1.73 (1.10 to 2.71) |
| Diarrhea | 4 (12.1) | 8 (25.0) | 1.47 (0.90 to 2.42) |
Values are given as n (%) or as otherwise indicated. Differences between baseline and 2-year follow-up have been tested using Fisher’s exact test. 95% CI, 95% confidence interval.